PT - JOURNAL ARTICLE AU - Dalang Yu AU - Xiao Yang AU - Bixia Tang AU - Yi-Hsuan Pan AU - Jianing Yang AU - Junwei Zhu AU - Guangya Duan AU - Zi-Qian Hao AU - Hailong Mu AU - Long Dai AU - Wangjie Hu AU - Mochen Zhang AU - Ying Cui AU - Tong Jin AU - Cui-Ping Li AU - Lina Ma AU - Language translation team AU - Xiao Su AU - Guoqing Zhang AU - Wenming Zhao AU - Haipeng Li TI - Coronavirus GenBrowser for monitoring the transmission and evolution of SARS-CoV-2 AID - 10.1101/2020.12.23.20248612 DP - 2021 Jan 01 TA - medRxiv PG - 2020.12.23.20248612 4099 - http://medrxiv.org/content/early/2021/04/30/2020.12.23.20248612.short 4100 - http://medrxiv.org/content/early/2021/04/30/2020.12.23.20248612.full AB - A large volume of SARS-CoV-2 genomic data has accumulated. To timely analyze and visualize the exponentially increasing viral genomic sequences, we developed the Coronavirus GenBrowser (CGB) based on the framework of distributed genome alignments and the evolutionary tree built on an existing subtree. All 98,496 internal nodes were named by CGB binary nomenclature. Among the 330,942 high-quality SARS-CoV-2 genomic sequences analyzed, 253,798 mutations and 971 mutation cold spots were identified. This analysis also revealed a strain dated early March 2020 causing an outbreak in Beijing after three months of dormancy. Three prevalent European variants were found to have no mutations in three months. Another strain with S:D614G was found to have 671 identical descendants spreading in six continents between February 2020 and January 2021. Mutation-dormant strains provide evidences of cold-chain related transmission. Results of this study show that CGB is an efficient platform for monitoring the dynamics of SARS-CoV-2 transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the National Key Research and Development Project (No. 2020YFC0847000).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe coronavirus genomic sequences used in this study were obtained from the 2019nCoVR database 11. Timely updated data of genomic sequences of SARS-CoV-2 variants are shared with the general public at https://bigd.big.ac.cn/ncov/apis/. The free software (desktop and web-based versions) can be downloaded from http://www.egps-software.net/.